An extraction of diagnostic and risk markers from this dataset, yields 4160 biomarkers for pancreatic and liver cancers. Table gives statistics on some core entities and tags related to biomarkers from the dataset. When assessing potential markers that can be used for diagnosis or risk classification, there are a total of 1163 and 3582 in pancreatic and liver cancer, respectively. These markers have been measured using varied specimens. Figure shows the representation of the top 10 categories of diagnostic or risk biomarkers in combination to the specimen they were measured in. Figure is a graphical representation on how the biomarkers are shared between the two indications. There are 1007 biomarkers associated exclusively with pancreatic cancer and 3094 exclusive to liver cancer. 425 markers are shared between the two indications. It would be interesting and valuable to assess promising markers from that shared set which could be utilized in both indications. Figure shows the count of biomarkers classified by biomarker type (Figure ) and by specimen (Figure ). mRNA markers are the leading type markers for liver cancer, while proteins are the most abundant type markers for pancreatic cancer. Blood samples dominate for both type of cancers.